Revvity Divests China Immunodiagnostics Unit to Focus on High-Growth Sectors

Key Facts

In a strategic move to enhance the quality of its future earnings, Revvity has announced its intention to divest its immunodiagnostics business unit in China. According to reports, this specific segment accounts for approximately 6% of the company's total annual revenue. The divestiture is designed to mitigate ongoing policy and funding challenges within the Chinese healthcare market while pivoting the corporate focus toward higher-margin life sciences and software sectors.

This exit comes as global healthcare firms face mounting pressure in China due to Volume-Based Procurement (VBP) policies that have significantly compressed margins. In comparison to peers, Thermo Fisher Scientific recently noted a slowdown in Chinese demand, while Agilent Technologies lowered its annual guidance citing weak regional spending per market data. Revvity’s move represents a proactive attempt to reduce exposure to these structural headwinds.

Shares of RVTY stood at $101.29 at close June 10, 2026, having reached an intraday high of $106.21. Investors will now focus on how the proceeds from this sale are redeployed into the company's software and high-growth segments. On the macro front, market participants are monitoring global inflation trends following the U.S. Non-Farm Payrolls report on June 5, 2026, which showed an addition of 172,000 jobs.